Personalized Medicine Universe最新文献_第4页

Lifestyle medicine – An evidence based approach to nutrition, sleep, physical activity, and stress management on health and chronic illness 生活方式医学-以证据为基础的营养，睡眠，身体活动，健康和慢性疾病的压力管理方法

Personalized Medicine Universe Pub Date : 2019-07-01 DOI: 10.1016/j.pmu.2019.05.002

Minako Abe , Hiroyuki Abe

引用次数: 18

Personalized care using thermobalancing therapy can help men with chronic prostatitis and chronic pelvic pain to recover 个性化护理使用热平衡疗法可以帮助男性慢性前列腺炎和慢性盆腔疼痛的恢复

Personalized Medicine Universe Pub Date : 2019-07-01 DOI: 10.1016/j.pmu.2019.04.002

Simon Allen

{"title":"Personalized care using thermobalancing therapy can help men with chronic prostatitis and chronic pelvic pain to recover","authors":"Simon Allen","doi":"10.1016/j.pmu.2019.04.002","DOIUrl":"10.1016/j.pmu.2019.04.002","url":null,"abstract":"<div><h3>Introduction</h3><p>The incidence of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is high. Thermobalancing therapy (TT) with Dr Allen's Therapeutic Device (DATD) improves the condition of men with CP/CPPS by treating the cause of this disease. The aim of this study is to improve management of CP/CPPS.</p></div><div><h3>Methods</h3><p>A clinical trial<span> observed the dynamics of clinical characteristics and parameters in 45 men with CP/CPPS who used DATD, before and after a 6-month period of therapy, and in a no-treatment group. Evaluation used Chronic Prostatitis Symptom Index pain score, quality of life (QoL), and prostate volume (PV).</span></p></div><div><h3>Results</h3><p>The outcomes confirmed that DATD decreases PV from 31 mL to 27 mL (<em>P</em> < 0.001), reduces pain score from 10.3 to 3.5 (<em>P</em> < 0.001), and improves QoL from 8.1 to 2.9 (<em>P</em> < 0.001), with no changes seen in the control group.</p></div><div><h3>Conclusion</h3><p>Personalized care of patients with CP/CPPS by using TT enables this disease to be effectively and safely managed at home, helping to diminish pharmacological intervention and reduce healthcare costs.</p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"8 ","pages":"Pages 48-52"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2019.04.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76592912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Lifestyle medicine – An evidence based approach to nutrition, sleep, physical activity, and stress management on health and chronic illness 生活方式医学-以证据为基础的营养，睡眠，身体活动，健康和慢性疾病的压力管理方法

Personalized Medicine Universe Pub Date : 2019-07-01 DOI: 10.1016/J.PMU.2019.05.002

Minako Abe, H. Abe

引用次数: 19

Cloning and expansion of antigen-specific T cells using iPS cell technology: Possible use of regenerated T cells in personalized medicine 利用iPS细胞技术克隆和扩增抗原特异性T细胞:再生T细胞在个性化医疗中的可能应用

Personalized Medicine Universe Pub Date : 2018-07-01 DOI: 10.1016/j.pmu.2018.05.002

Hiroshi Kawamoto , Kyoko Masuda , Seiji Nagano

{"title":"Cloning and expansion of antigen-specific T cells using iPS cell technology: Possible use of regenerated T cells in personalized medicine","authors":"Hiroshi Kawamoto , Kyoko Masuda , Seiji Nagano","doi":"10.1016/j.pmu.2018.05.002","DOIUrl":"10.1016/j.pmu.2018.05.002","url":null,"abstract":"<div><p><span>Recent advances in adoptive immunotherapy<span> using cytotoxic T lymphocytes (CTLs) have demonstrated that CTLs are effective in killing tumor cells </span></span><em>in vivo</em><span> for some tumor types. However, a critical issue that CTLs collected from patients are easily exhausted during expansion culture is yet to be addressed. Therefore, we have been developing a strategy that utilizes induced pluripotent stem cell<span> (iPSC) technology, based on the idea that iPSCs produced from antigen-specific CTLs would regenerate CTLs with the same antigen specificity as the original CTLs. We previously succeeded in regenerating melanoma antigen<span> MART1-specific CTLs, and more recently in producing potent CTLs expressing the CD8αβ heterodimer<span><span>. We are now developing a novel method by which non-T derived iPSCs are transduced with exogenous T cell receptor (TCR) genes. If this method is applied to the allogeneic transfusion setting wherein HLA haplotype-homozygous iPSC stocks are used as the cell source, it will be possible to prepare “off-the-shelf” </span>T cells<span>. We are also considering incorporation of a personalized medicine approach to this allogeneic setting. In such a scheme, genes encoding TCRs specific for neoantigens will be collected from patients and HLA-homo iPSCs will be transduced with these TCR genes. Using such iPSCs, it will be possible to produce allogeneic CTLs expressing autologous TCRs originating from patients.</span></span></span></span></span></p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"7 ","pages":"Pages 7-12"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2018.05.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89108786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Novel biologic products and Post-Bio strategy 新型生物制品和后生物策略

Personalized Medicine Universe Pub Date : 2018-07-01 DOI: 10.1016/j.pmu.2018.03.001

Kusuki Nishioka

引用次数: 0

Significance of humanized mouse models for evaluating humoral immune response against cancer vaccines 人源化小鼠模型评价肿瘤疫苗体液免疫应答的意义

Personalized Medicine Universe Pub Date : 2018-07-01 DOI: 10.1016/j.pmu.2018.04.002

Yoshie Kametani , Asuka Miyamoto , Toshiro Seki , Ryoji Ito , Sonoko Habu , Yutaka Tokuda

{"title":"Significance of humanized mouse models for evaluating humoral immune response against cancer vaccines","authors":"Yoshie Kametani , Asuka Miyamoto , Toshiro Seki , Ryoji Ito , Sonoko Habu , Yutaka Tokuda","doi":"10.1016/j.pmu.2018.04.002","DOIUrl":"10.1016/j.pmu.2018.04.002","url":null,"abstract":"<div><p><span><span>Because accumulation of mutations produces unique neoantigen patterns in cancer cells, it has been hypothesized that these patterns are recognized by the patients' immune system. Therefore, the development of cancer vaccines has been challenging owing to the possibility of an anti-cancer effect induced by the immune system against such neoantigens. However, it is difficult to develop effective vaccines because of the variety of </span>mutations induced<span><span><span> in cancer cells and human leukocyte antigen (HLA), which is predicted to present the neoantigen-derived peptides. Moreover, the activation of cancer-specific </span>cytotoxic cells is inhibited by cancer cell immunoediting in each patient. Although </span>cellular immunity can be analyzed </span></span><em>ex vivo</em><span><span>, there are no definite methods to evaluate humoral immunity. A humanized mouse model has been developed and used for evaluating the multipotency of </span>hematopoietic stem cells. Presently, significant improvements in the humanized mouse model approach have partially recapitulated human humoral immunity </span><em>in vivo</em><span>, and human antibody production<span><span> can be induced in the mouse model. These mice can be used to produce new cancer vaccines and to establish polypharmacy protocols in a preclinical model. In this review, we discuss the preclinical evaluation of the cancer vaccines using humanized mice transferred with patient-derived </span>peripheral blood mononuclear cells (PBMCs) to advance a personalized medicine approach.</span></span></p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"7 ","pages":"Pages 13-18"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2018.04.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89770460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Predictive factors for the development of bronchial asthma by the age of 3 3岁前支气管哮喘发展的预测因素

Personalized Medicine Universe Pub Date : 2018-07-01 DOI: 10.1016/j.pmu.2018.04.001

Naomi Kondo , Eiko Matsui , Takahide Teramoto , Manami Kuwabara , Tomiko Nagata , Yayoi Furuta , Masayo Sanada , Ikuko Aoki , Masumi Kumada

引用次数: 1

Assessing antitumor and T cell immune responses by cytokine assay in cancer patients treated with immunotherapy – A pilot study 通过细胞因子测定评估免疫治疗癌症患者的抗肿瘤和T细胞免疫反应-一项初步研究

Personalized Medicine Universe Pub Date : 2018-07-01 DOI: 10.1016/j.pmu.2018.05.001

Ayumi Morokuma, Yukie Saeki, Ayaka Nakamura, Hazuki Sakuma, Yoshimori Ishihara, Minako Abe

{"title":"Assessing antitumor and T cell immune responses by cytokine assay in cancer patients treated with immunotherapy – A pilot study","authors":"Ayumi Morokuma, Yukie Saeki, Ayaka Nakamura, Hazuki Sakuma, Yoshimori Ishihara, Minako Abe","doi":"10.1016/j.pmu.2018.05.001","DOIUrl":"10.1016/j.pmu.2018.05.001","url":null,"abstract":"<div><p><span>Clinical evaluation<span><span> methods for therapeutic effectiveness based on scientific evidence are desired as tools for contributing to therapeutic strategies and advancements in cancer immunotherapy research. By quantitatively measuring multiple immune response factors responsible for </span>T cell<span> activity and cytotoxic activity, we can be expected to evaluate a patient's immune response. We used plasma samples of human peripheral blood and compared the T cell and antitumor immune response by measuring various immune related cytokines (TNFα, sCD137, IL-2, IL-5, INFɤ, Perforin, </span></span></span>Granzyme A<span>, Granzyme B<span><span>, IL-10, IL-4). In this pilot study, we compared samples from healthy donors with those from cancer patients treated with multivalent dendritic cell (DC) vaccines and natural killer (NK) cell immunotherapy<span> before and after treatment. We examined the usefulness of this method as a biomarker to assess the therapeutic effectiveness of </span></span>immune cell therapy by statistical analysis and by plotting a cancer immunogram correlating patient data with clinical outcomes.</span></span></p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"7 ","pages":"Pages 28-33"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2018.05.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83802678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of MTHF 677TT with adverse drug reactions and RFC G80A with non-response and adverse drug reactions in methotrexate therapy 甲氨蝶呤治疗中MTHF 677TT与药物不良反应、RFC G80A与无反应及药物不良反应的关系

Personalized Medicine Universe Pub Date : 2018-07-01 DOI: 10.1016/j.pmu.2018.01.001

Manahel Mahmood AlSabbagh

{"title":"Association of MTHF 677TT with adverse drug reactions and RFC G80A with non-response and adverse drug reactions in methotrexate therapy","authors":"Manahel Mahmood AlSabbagh","doi":"10.1016/j.pmu.2018.01.001","DOIUrl":"10.1016/j.pmu.2018.01.001","url":null,"abstract":"<div><p><span><span>Being an anti-metabolite and anti-inflammatory agent, Methotrexate, a </span>folate<span><span> analogue, is indicated for a wide spectrum of diseases including moderate to severe chronic inflammatory disorders like </span>psoriasis<span> and rheumatoid arthritis<span> and malignant diseases such as childhood acute lymphoblastic leukaemia and </span></span></span></span>choriocarcinoma<span><span>. The outcome of Methotrexate treatment varies. Though up to 50% of patients with inflammatory disorders show a favourable response; one third discontinues Methotrexate due to </span>adverse drug reactions<span> or non-response. Such diversity suggests an inter-individual variation due to multiple factors including genetic polymorphisms. This review was conducted to identify genotypes predictive of Methotrexate treatment outcome. More than 15 alleles located in eight genes were explored by over 25 studies. Among those, we identified MTHFrs1801133TT genotype to be likely associated with adverse drug reactions and RFCrs1051266A allele to be associated with both, non-response and adverse drug reactions. We recommend the conduction of meta-analysis to verify these findings.</span></span></p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"7 ","pages":"Pages 19-27"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2018.01.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82761249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Personalized medicine for connective tissue disease: Historical and future perspectives 结缔组织疾病的个性化医疗:历史和未来的观点

Personalized Medicine Universe Pub Date : 2018-07-01 DOI: 10.1016/j.pmu.2018.04.004

Masataka Kuwana

{"title":"Personalized medicine for connective tissue disease: Historical and future perspectives","authors":"Masataka Kuwana","doi":"10.1016/j.pmu.2018.04.004","DOIUrl":"10.1016/j.pmu.2018.04.004","url":null,"abstract":"<div><p><span>Connective tissue disease<span><span><span><span> (CTD), previously termed collagen disease, is a group of disorders, characterized by rheumatic symptoms, autoimmunity, and degeneration of the pathohistology of the </span>extracellular matrix. Better classification and disease subsetting, as well as introduction of </span>immunosuppressants and molecular-targeting </span>drugs, have much improved patients' </span></span>quality of life<span><span> and prognosis. The treat-to-target strategy in combination with emphasis on early diagnosis and intervention is now advocated for many CTDs. However, there remains a need to determine the appropriate management for individual patients, as clinical presentation and treatment response are highly variable among patients. A personalized medicine approach based on comprehensive patient profiles can improve patient care and long-term outcomes by decreasing the number of treatment failures, improving drug safety, and reducing the complications and organ damage associated with the disease and its treatment. Tremendous efforts have been made to identify patients who require early aggressive treatment, but the current knowledge on predicting the treatment response to individual drugs is limited. Better coordination between basic and </span>clinical science is the key to providing a basis for tailored approaches for individual patients with CTD.</span></p></div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"7 ","pages":"Pages 1-6"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2018.04.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73201618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0